Inflammation and neurodegeneration in Parkinson's disease
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Self-citationOxidative stress in Parkinson's disease
Jenner, P. (2003) · Annals of Neurology · doi:10.1002/ana.10483 · Cited by 2,053
Liu, B., & Hong, J.-S. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035048 · Cited by 1,095
Mogi, M., Harada, M., Riederer, P., Narabayashi, H., Fujita, K., & Nagatsu, T. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90746-3 · Cited by 986
Nonsteroidal Anti-inflammatory Drugs and the Risk of Parkinson Disease
Chen, H., Zhang, S. M., Hernán, M. A., Schwarzschild, M. A., Willett, W. C., Colditz, G. A., Speizer, F. E., & Ascherio, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1059 · Cited by 634
Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease
Boka, G., Anglade, P., Wallach, D., Javoy-Agid, F., Agid, Y., & Hirsch, E. C. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90684-x · Cited by 590
Mitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease
BEAL, M. F. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07470.x · Cited by 523
Inflammatory processes in Alzheimer's disease
McGeer, E. G., & McGeer, P. L. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00124-6 · Cited by 472
Self-citationThe Role of Glial Reaction and Inflammation in Parkinson's Disease
HIRSCH, E. C., BREIDERT, T., ROUSSELET, E., HUNOT, S., HARTMANN, A., & MICHEL, P. P. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07478.x · Cited by 449
Distinct Role for Microglia in Rotenone-Induced Degeneration of Dopaminergic Neurons
Gao, H.-M., Hong, J.-S., Zhang, W., & Liu, B. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-03-00782.2002 · Cited by 439
Cited by
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609
Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines
Rea, I. M., Gibson, D. S., McGilligan, V., McNerlan, S. E., Alexander, H. D., & Ross, O. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00586 · Cited by 1,267
“Neurodegenerative Disease Inflammation has been well established as a major component of neurodegenerative disorders, but it has never been clear if this was a direct cause of the disease or a consequence of the progressive degenerative process that was occurring (363, 364).”
BackgroundEpidemiology and etiology of Parkinson's disease: a review of the evidence
Wirdefeldt, K., Adami, H.-O., Cole, P., Trichopoulos, D., & Mandel, J. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9581-6 · Cited by 1,199
Xu, M., Tchkonia, T., Ding, H., Ogrodnik, M., Lubbers, E. R., Pirtskhalava, T., White, T. A., Johnson, K. O., Stout, M. B., Mezera, V., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1515386112 · Cited by 915
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Kregel, K. C., & Zhang, H. J. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00327.2006 · Cited by 883
The role of the anaphylatoxins in health and disease
Klos, A., Tenner, A. J., Johswich, K.-O., Ager, R. R., Reis, E. S., & Köhl, J. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.04.027 · Cited by 730
Glial reactions in Parkinson's disease
McGeer, P. L., & McGeer, E. G. (2008) · Movement Disorders · doi:10.1002/mds.21751 · Cited by 701
Self-citationAlternatively activated microglia and macrophages in the central nervous system
Franco, R., & Fernández-Suárez, D. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.05.003 · Cited by 650
Inflammation as a causative factor in the aetiology of Parkinson's disease
Whitton, P. S. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707167 · Cited by 624
Pathogenesis of Parkinson disease—the gut–brain axis and environmental factors
Klingelhoefer, L., & Reichmann, H. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.197 · Cited by 598
Common mechanisms of amyloid oligomer pathogenesis in degenerative disease
Glabe, C. G. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.04.017 · Cited by 569
“Chronic inflammation may also be a component of the core degenerative pathway as it is frequently observed in neurodegenerative diseases [19,20, 45 ].”
BackgroundPeripheral cytokines profile in parkinson’s disease
Reale, M., Iarlori, C., Thomas, A., Gambi, D., Perfetti, B., Di Nicola, M., & Onofrj, M. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2008.07.003 · Cited by 547
“…levels of proinflammatory cytokines and neurotrophins in the brain of PD patients, thus suggesting that neuroinflammation and apoptosis may contribute to the pathogenesis of PD (Nagatsu and Sawada, 2005; Sawada et al., 2006; McGeer et al., 1988; McGeer and McGeer, 2004; Tansey et al., 2007, 2008).”
Pan-Montojo, F., Anichtchik, O., Dening, Y., Knels, L., Pursche, S., Jung, R., Jackson, S., Gille, G., Spillantini, M. G., Reichmann, H., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008762 · Cited by 524
“It has been postulated that mitochondrial dysfunction [27], oxidative stress [28], inflammatory response [29] and protein mishandling may play an important role in the pathogenesis of sporadic PD [30].”
BackgroundInflammation and the Degenerative Diseases of Aging
McGEER, P. L., & McGEER, E. G. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1332.007 · Cited by 518
Self-citationWill the real multiple sclerosis please stand up?
Stys, P. K., Zamponi, G. W., van Minnen, J., & Geurts, J. J. G. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3275 · Cited by 475
Long-term PM 2.5 Exposure and Neurological HospitalAdmissions in the Northeastern United States
Kioumourtzoglou, M.-A., Schwartz, J. D., Weisskopf, M. G., Melly, S. J., Wang, Y., Dominici, F., & Zanobetti, A. (2016) · Environmental Health Perspectives · doi:10.1289/ehp.1408973 · Cited by 466
Oxidative Stress in Parkinson's Disease: A Mechanism of Pathogenic and Therapeutic Significance
Zhou, C., Huang, Y., & Przedborski, S. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.023 · Cited by 450
The pathogenesis of cell death in Parkinson's disease
Jenner, P., & Olanow, C. W. (2006) · Neurology · doi:10.1212/wnl.66.10_suppl_4.s24 · Cited by 446
Glaucoma as a neurodegenerative disease
Gupta, N., & Yücel, Y. H. (2007) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e3280895aea · Cited by 422
Parainflammation, Chronic Inflammation and Age-Related Macular Degeneration
Chen, M., & Xu, H. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.3ri0615-239r · Cited by 381
“evidence suggests that a low-grade chronic inflammation contributes critically to many human diseases that were previously not considered as inflammatory disorders, including obesity [1, 2], atherosclerosis [2-4], and various neurodegenerative disorders [3, 5-8].”
BackgroundMolecular mechanisms of aging-associated inflammation
Sarkar, D., & Fisher, P. B. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.04.009 · Cited by 359
Genome-wide pleiotropy between Parkinson disease and autoimmune diseases
Witoelar, A., Jansen, I. E., Wang, Y., Desikan, R. S., Gibbs, J. R., Blauwendraat, C., Thompson, W. K., Hernandez, D. G., Djurovic, S., Schork, A. J., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.0469 · Cited by 352
The relevance of iron in the pathogenesis of Parkinson’s disease
Sian‐Hülsmann, J., Mandel, S., Youdim, M. B. H., & Riederer, P. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07132.x · Cited by 352
Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson’s Disease
Subramaniam, S. R., & Federoff, H. J. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00176 · Cited by 347
Prospective study of dietary pattern and risk of Parkinson disease
Gao, X., Chen, H., Fung, T. T., Logroscino, G., Schwarzschild, M. A., Hu, F. B., & Ascherio, A. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.5.1486 · Cited by 338
Pott Godoy, M. C., Tarelli, R., Ferrari, C. C., Sarchi, M. I., & Pitossi, F. J. (2008) · Brain · doi:10.1093/brain/awn101 · Cited by 335
“Activated microglia are found in the SN of Parkinson’s disease brains (McGeer et al., 1988; Hunot et al., 1999; Hirsch et al., 2003; McGeer and McGeer, 2004) and in animal models (Mirza et al., 2000; Vila et al., 2001; Gao et al., 2002; Depino et al., 2003; Ferrari et al., 2006); thus, inflammatory…”
BackgroundPeripheral Inflammatory Biomarkers and Risk of Parkinson's Disease
Chen, H., O'Reilly, E. J., Schwarzschild, M. A., & Ascherio, A. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm260 · Cited by 317
Role of complement in neurodegeneration and neuroinflammation
BONIFATI, D., & KISHORE, U. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2006.03.007 · Cited by 313
Dodiya, H. B., Forsyth, C. B., Voigt, R. M., Engen, P. A., Patel, J., Shaikh, M., Green, S. J., Naqib, A., Roy, A., Kordower, J. H., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.12.012 · Cited by 305
Head injury and Parkinson's disease risk in twins
Goldman, S. M., Tanner, C. M., Oakes, D., Bhudhikanok, G. S., Gupta, A., & Langston, J. W. (2006) · Annals of Neurology · doi:10.1002/ana.20882 · Cited by 297
Exploring the Role of Neuroplasticity in Development, Aging, and Neurodegeneration
Marzola, P., Melzer, T., Pavesi, E., Gil-Mohapel, J., & Brocardo, P. S. (2023) · Brain Sciences · doi:10.3390/brainsci13121610 · Cited by 281
Wang, W., Nguyen, L. T. T., Burlak, C., Chegini, F., Guo, F., Chataway, T., Ju, S., Fisher, O. S., Miller, D. W., Datta, D., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610099113 · Cited by 270
Zhang, F., Liu, J., & Shi, J.-S. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.03.043 · Cited by 264
Dysregulated Lipid Metabolism and Its Role in α-Synucleinopathy in Parkinson’s Disease
Alecu, I., & Bennett, S. A. L. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00328 · Cited by 258
Bartels, A. L., Willemsen, A. T. M., Kortekaas, R., de Jong, B. M., de Vries, R., de Klerk, O., van Oostrom, J. C. H., Portman, A., & Leenders, K. L. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-008-0030-y · Cited by 258
Cellular and Molecular Mediators of Neuroinflammation in the Pathogenesis of Parkinson’s Disease
More, S. V., Kumar, H., Kim, I. S., Song, S.-Y., & Choi, D.-K. (2013) · Mediators of Inflammation · doi:10.1155/2013/952375 · Cited by 258
Sanchez-Guajardo, V., Febbraro, F., Kirik, D., & Romero-Ramos, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008784 · Cited by 256
“There are several lines of study indicating that activation of microglia, with subsequent production of pro-inflammatory cytokines, aggravates the neurodegenerative process in PD [3,4].”
BackgroundRole of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys
Miklossy, J., Doudet, D. D., Schwab, C., Yu, S., McGeer, E. G., & McGeer, P. L. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2005.10.034 · Cited by 255
Self-citationMicroglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration
Purisai, M. G., McCormack, A. L., Cumine, S., Li, J., Isla, M. Z., & Di Monte, D. A. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.10.008 · Cited by 254
Role of α-Synuclein in Inducing Innate and Adaptive Immunity in Parkinson Disease
Allen Reish, H. E., & Standaert, D. G. (2015) · Journal of Parkinson’s Disease · doi:10.3233/jpd-140491 · Cited by 244
Inflammation is genetically implicated in Parkinson’s disease
Dzamko, N., Geczy, C. L., & Halliday, G. M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.10.028 · Cited by 222
Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy
Schapansky, J., Nardozzi, J. D., Felizia, F., & LaVoie, M. J. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu138 · Cited by 226
6-Hydroxydopamine-induced alterations in blood-brain barrier permeability
Carvey, P. M., Zhao, C. H., Hendey, B., Lum, H., Trachtenberg, J., Desai, B. S., Snyder, J., Zhu, Y. G., & Ling, Z. D. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04281.x · Cited by 218
“Thus, microgliosis and astrocytosis are prevalent in the SN of PD patients (McGeer & McGeer, 2004b), the inducible form of nitric oxide synthase (iNOS) and cyclooxygenase 1- and 2-containing microglia are elevated (Knott et al., 2000), while the reduced form of glutathione is decreased, all…”
BackgroundThe beneficial effects of fruit polyphenols on brain aging
Lau, F. C., Shukitt-Hale, B., & Joseph, J. A. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.08.007 · Cited by 217
Morale, M. C., Serra, P. A., L’Episcopo, F., Tirolo, C., Caniglia, S., Testa, N., Gennuso, F., Giaquinta, G., Rocchitta, G., Desole, M. S., et al. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2005.07.060 · Cited by 207
de Pablos, R. M., Herrera, A. J., Espinosa-Oliva, A. M., Sarmiento, M., Muñoz, M. F., Machado, A., & Venero, J. L. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-34 · Cited by 201
“proteasome system and neuroinflammatory mechanisms are thought to collaborate in the progressive demise of SNpc neurons [1,2,5-11].”
BackgroundCellular and molecular mechanisms of immunomodulation in the brain through environmental enrichment
Singhal, G., Jaehne, E. J., Corrigan, F., & Baune, B. T. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00097 · Cited by 186
TNF-α knockout and minocycline treatment attenuates blood–brain barrier leakage in MPTP-treated mice
Zhao, C., Ling, Z., Newman, M. B., Bhatia, A., & Carvey, P. M. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.11.012 · Cited by 183
“While the etiology of PD remains unclear, both genetic factors and environmental toxins have been proposed in its pathogenesis (Ladeby et al., 2005; McGeer and McGeer, 2004).”
BackgroundInhibition of glial inflammatory activation and neurotoxicity by tricyclic antidepressants
Hwang, J., Zheng, L. T., Ock, J., Lee, M. G., Kim, S.-H., Lee, H.-W., Lee, W.-H., Park, H.-C., & Suk, K. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.045 · Cited by 181
Marchetti, B., & Abbracchio, M. P. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.08.007 · Cited by 175
Inflammation, the complement system and the diseases of aging
McGeer, E. G., Klegeris, A., & McGeer, P. L. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.08.008 · Cited by 170
Self-citationNeuroinflammation in Parkinson's disease: role in neurodegeneration and tissue repair
Vivekanantham, S., Shah, S., Dewji, R., Dewji, A., Khatri, C., & Ologunde, R. (2015) · International Journal of Neuroscience · doi:10.3109/00207454.2014.982795 · Cited by 171
“Neuroinflammation & Neurodegeneration in PD The characteristic features of neuroinflammation include activated microglia, reactive astrocytes within brain parenchyma and the release of numerous inflammatory mediators including cytokines, chemokines, PGs, complement cascade proteins, ROSs and RNSs.”
BackgroundZhang, S., Wang, X.-J., Tian, L.-P., Pan, J., Lu, G.-Q., Zhang, Y.-J., Ding, J.-Q., & Chen, S.-D. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-154 · Cited by 154
“To further confirm a relationship between CD200CD200R signalling and neuroinflammation in PD, we assayed several molecules that would be secreted by activated microglia in the proinflammatory stage [10,55-59].”
MethodDrouin-Ouellet, J., St-Amour, I., Saint-Pierre, M., Lamontagne-Proulx, J., Kriz, J., Barker, R. A., & Cicchetti, F. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu103 · Cited by 153
“It has in fact long been recognized that PD brains are characterized by the presence of a microglial reaction (McGeer et al., 1988; McGeer and McGeer, 2004), which increases with disease duration (Croisier et al., 2005).”
BackgroundPienaar, I. S., Lee, C. H., Elson, J. L., McGuinness, L., Gentleman, S. M., Kalaria, R. N., & Dexter, D. T. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.12.006 · Cited by 125
“31, and is considered the human homologue of MHC II (McGeer and McGeer, 2004).”
Mitophagy and cGAS–STING crosstalk in neuroinflammation
Zhou, X., Wang, J., Yu, L., Qiao, G., Qin, D., Yuen-Kwan Law, B., Ren, F., Wu, J., & Wu, A. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.05.012 · Cited by 131
Neuroinflammation: a potential therapeutic target
Craft, J. M., Watterson, D. M., & Van Eldik, L. J. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.5.887 · Cited by 116
Paknahad, Z., Sheklabadi, E., Derakhshan, Y., Bagherniya, M., & Chitsaz, A. (2020) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2020.102366 · Cited by 113
García-Domínguez, I., Veselá, K., García-Revilla, J., Carrillo-Jiménez, A., Roca-Ceballos, M. A., Santiago, M., de Pablos, R. M., & Venero, J. L. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00398 · Cited by 111
“In this regard, clinical and experimental evidence suggests that PD is associated with neuroinflammatory processes such as microglia activation, T-leukocyte infiltration, and blood–brain barrier (BBB) dysfunction (McGeer and McGeer, 2004; Hirsch and Hunot, 2009; Tiwari and Pal, 2017).”
BackgroundLópez González, I., Garcia-Esparcia, P., Llorens, F., & Ferrer, I. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020206 · Cited by 101
“This has been tested in vivo using positron emission tomography (PET) with specific ligands, in the CSF and in post-mortem brains [4,122,127,133–138].”
BackgroundMethodResultHernández-Romero, M. C., Delgado-Cortés, M. J., Sarmiento, M., de Pablos, R. M., Espinosa-Oliva, A. M., Argüelles, S., Bández, M. J., Villarán, R. F., Mauriño, R., Santiago, M., et al. (2012) · NeuroToxicology · doi:10.1016/j.neuro.2012.01.018 · Cited by 100
Chen, M., Muckersie, E., Robertson, M., Forrester, J. V., & Xu, H. (2008) · Experimental Eye Research · doi:10.1016/j.exer.2008.09.005 · Cited by 99
Increased peripheral inflammation in asymptomatic leucine‐rich repeat kinase 2 mutation carriers
Dzamko, N., Rowe, D. B., & Halliday, G. M. (2016) · Movement Disorders · doi:10.1002/mds.26529 · Cited by 98
Properdin and factor h: Opposing players on the alternative complement pathway “see-saw”
Kouser, L., Abdul-Aziz, M., Nayak, A., Stover, C. M., Sim, R. B., & Kishore, U. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00093 · Cited by 91
“Complement proteins are known to be expressed in neurons, microglia, astrocytes, and oligodendrocytes (McGeer and McGeer, 2004).”
BackgroundMarioni, R. E., Stewart, M. C., Murray, G. D., Deary, I. J., Fowkes, F. G. R., Lowe, G. D. O., Rumley, A., & Price, J. F. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181b1e538 · Cited by 86
“Tumor necrosis factor- also stimulates the production of fibrinogen (33) and (indirectly via synthesis of interleukin-6) CRP (34), which along with other cytokines and products of the complement cascade activate the microglia (35).”
BackgroundPotential Treatment of Parkinson’s Disease with Omega-3 Polyunsaturated Fatty Acids
Li, P., & Song, C. (2022) · Nutritional Neuroscience · doi:10.1080/1028415x.2020.1735143 · Cited by 74
Morais, L. H., Hara, D. B., Bicca, M. A., Poli, A., & Takahashi, R. N. (2018) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000389 · Cited by 58
Ho, S.-C., Hsu, C.-C., Pawlak, C. R., Tikhonova, M. A., Lai, T.-J., Amstislavskaya, T. G., & Ho, Y.-J. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.04.022 · Cited by 65
Dal Pra, I., Chiarini, A., Nemeth, E. F., Armato, U., & Whitfield, J. F. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20511 · Cited by 47
Qiao, C.-M., Quan, W., Zhou, Y., Niu, G.-Y., Hong, H., Wu, J., Zhao, L.-P., Li, T., Cui, C., Zhao, W.-J., et al. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03392-x · Cited by 45
Glia-derived extracellular vesicles in parkinson’s disease.
Marchetti, B., Leggio, L., L’Episcopo, F., Vivarelli, S., Tirolo, C., Paternò, G., Giachino, C., Caniglia, S., Serapide, M. F., & Iraci, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061941 · Cited by 38
Liu, D., Guo, J.-J., Su, J.-H., Svanbergsson, A., Yuan, L., Haikal, C., Li, W., Gouras, G., & Li, J.-Y. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00242-5 · Cited by 32
TRPMLs and TPCs: targets for lysosomal storage and neurodegenerative disease therapy?
Krogsaeter, E., Rosato, A. S., & Grimm, C. (2022) · Cell Calcium · doi:10.1016/j.ceca.2022.102553 · Cited by 31
Neel, D. V., Basu, H., Gunner, G., & Chiu, I. M. (2022) · Immunological Reviews · doi:10.1111/imr.13083 · Cited by 22
Emerging roles of leptin in Parkinson’s disease: Chronic inflammation, neuroprotection and more?
Regensburger, M., Rasul Chaudhry, S., Yasin, H., Zhao, Y., Stadlbauer, A., Buchfelder, M., & Kinfe, T. (2023) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2022.09.010 · Cited by 17
Metadata
- Authors
- McGeer, P. L., & McGeer, E. G.
- Venue
- Parkinsonism & Related Disorders
- Publisher
- Elsevier BV
- Published
- 2004-05
- Volume
- 10
- Pages
- S3-S7
- ISSN
- 1353-8020 (ISSN-L)
- OpenAlex
- W2036600670
- Cited by
- 625
- References
- 41
- FWCI
- 22.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.